HEART评分在急诊胸痛中的联邦Meta分析性能评估
本研究为回顾性多中心观察性研究,覆盖6个急诊科,纳入2020年1月1日至2023年12月31日期间就诊且有记录HEART评分的成年胸痛患者,共57,906次急诊就诊,30天主要不良心血管事件(MACE30)发生率为2.2%。采用基于各中心2×2表的联邦双变量随机效应Meta分析评估HEART评分诊断性能,并与集中式患者层面分析比较。联邦Meta分析显示HEART评分具有高特异度和阴性预测值,符合其排除功能,汇总HSROC曲线下面积为0.759(95%CI 0.646-0.831);集中式分析AUROC为0.785(95%CI 0.776-0.794),两者差异小且临床意义有限。结论认为联邦诊断Meta分析可在保护隐私的前提下实现可扩展的多中心急诊风险分层工具评估。
要点
- 在57,906次有HEART评分的急诊胸痛就诊中,30天MACE30发生率为2.2%。
- 联邦Meta分析显示HEART评分具有高特异度和阴性预测值,符合其排除功能,中心间变异 modest。
- 联邦Meta分析汇总HSROC曲线下面积为0.759(95%CI 0.646-0.831)。
- 集中式患者层面分析AUROC为0.785(95%CI 0.776-0.794),与联邦估计差异小且临床意义有限。
- 联邦方法保留了中心间异质性和不同急诊科结局患病率的变异。
适用人群与场景
- 2020年1月1日至2023年12月31日期间6个急诊科就诊的成年胸痛患者,且有记录的HEART评分。
诊断标准与关键阈值
- MACE30定义为急性心肌梗死、冠状动脉血运重建或全因死亡。
- HEART评分诊断性能通过基于各中心2×2表的联邦双变量随机效应Meta分析评估,计算汇总敏感度、特异度和HSROC估计。
研究设计与关键结果
- 研究类型为回顾性、多中心观察性研究,覆盖6个急诊科,共57,906次有记录HEART评分的急诊就诊,MACE30发生率为2.2%。
- 联邦Meta分析显示HEART评分具有高特异度和阴性预测值,中心间变异 modest。
- 联邦Meta分析汇总HSROC曲线下面积为0.759(95%CI 0.646-0.831)。
- 集中式患者层面分析AUROC为0.785(95%CI 0.776-0.794)。
- 联邦与集中式估计差异小且临床意义有限,反映了中心间异质性和不同急诊科结局患病率变异的保留。
证据类型、等级与局限
- 证据类型:回顾性、多中心观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 联邦诊断Meta分析可生成与集中式患者层面数据密切一致的HEART评分性能估计,支持在保护隐私前提下对急诊风险分层工具进行可扩展的多中心评估。
- HEART评分在联邦分析中表现出高特异度和阴性预测值,符合其排除功能,但汇总HSROC曲线下面积为0.759,判别能力为中等。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Multicenter evaluation of emergency department (ED) risk stratification tools is often limited by barriers to patient-level data sharing. We used the HEART score as a clinical use case to evaluate whether a federated diagnostic meta-analytic approach yields performance estimates comparable to those obtained from centralized patient-level analysis for predicting 30-day major adverse cardiovascular events (MACE30).
METHODS: We conducted a retrospective, multicenter observational study across six EDs between January 1, 2020, and December 31, 2023. Adult patients presenting with chest pain who had a documented HEART score were included. MACE30 was defined as acute myocardial infarction, coronary revascularization, or all-cause mortality. The diagnostic performance of the HEART score was evaluated using a federated bivariate random-effects meta-analysis based on site-level 2 × 2 tables, yielding pooled sensitivity, specificity, and hierarchical summary receiver operating characteristic (HSROC) estimates. These results were compared with performance metrics derived from centralized patient-level analysis.
RESULTS: Among 57,906 ED encounters with documented HEART scores, MACE30 occurred in 2.2%. In federated meta-analysis, the HEART score demonstrated high specificity and negative predictive value, consistent with its intended rule-out function, with modest between-site variability. The pooled HSROC area under the curve was 0.759 (95% CI, 0.646-0.831). Centralized patient-level analysis yielded similar discrimination (AUROC 0.785; 95% CI, 0.776-0.794). Differences between federated and centralized estimates were small and clinically modest, reflecting preservation of site-level heterogeneity and variation in outcome prevalence across EDs.
CONCLUSIONS: Federated diagnostic meta-analysis produced HEART score performance estimates closely aligned with those obtained from centralized patient-level data. This approach enabled scalable, privacy-preserving multicenter evaluation of ED risk-stratification tools while accommodating heterogeneity across practice settings.
参考来源
- Wang H, Chou E, Robinson RD, et al. Federated Meta-Analysis of HEART Score Performance for Emergency Department Chest Pain. Acad Emerg Med. 2026. PMID: 41943236. doi:10.1111/acem.70284
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。